Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
X92001666 is a water-soluble topical lotion developed by Oystershell NV for the treatment of head lice (*Pediculus humanus capitis*). Marketed under the brand name Elimax, the product utilizes a physical mechanism of action, primarily suffocation, to eliminate lice and their eggs (nits). Unlike traditional pediculicides that contain neurotoxic insecticides such as pyrethrins or malathion, X92001666 blocks the respiratory spiracles of the lice, leading to hypoxia and death. The formulation is specifically designed to be water-soluble, allowing it to be applied to dry hair and easily rinsed out with standard shampoo, which distinguishes it from traditional oil-based suffocation agents like dimethicone. Clinical studies, including a randomized comparative trial against pyrethrin-based RID shampoo, have evaluated its efficacy and safety in pediatric and adult populations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on X92001666.